Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Gains Therapeutic Cancer Vaccine TroVax In Deal With Oxford BioMedica

This article was originally published in The Pink Sheet Daily

Executive Summary

Announcement of the $690 million deal comes one day ahead of an advisory committee meeting for Provenge, the first therapeutic cancer vaccine to reach FDA.

You may also be interested in...



Oxford BioMedica/Sanofi Make Headway With FDA On TroVax Cancer Vaccine

Drug makers reaffirm commitment to developing TroVax, a therapeutic vaccine for renal cancer and potentially colorectal cancer.

Oxford BioMedica/Sanofi Make Headway With FDA On TroVax Cancer Vaccine

Drug makers reaffirm commitment to developing TroVax, a therapeutic vaccine for renal cancer and potentially colorectal cancer.

Oxford BioMedica/Sanofi Make Headway With FDA On TroVax Cancer Vaccine

After facing a setback with the therapeutic cancer vaccine TroVax in July, partners Oxford BioMedica and Sanofi-Aventis are reaffirming their commitment to develop the vaccine for the treatment of renal cancer and potentially colorectal cancer following a meeting with FDA

Related Content

Topics

UsernamePublicRestriction

Register

PS065826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel